Skip to main content

Advertisement

SpringerLink
Log in

Intensive adjuvant chemotherapy for breast cancer

  • Published:
Breast Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

CMF:

Cyclophosphamide, methotrexate and 5-FU

ER:

Estrogen receptor

FEC:

5-FU, epirubicin and cyclophosphamide

PgR:

Progesterone receptor

References

  1. Henderson IC,et al: Improved disease-free survival and overall survival from the addition of sequential paclitaxel in the adjuvant chemotherapy of patients with node-positive primary breast cancer. ASCO Proc 1998, 390A.

  2. Saarto T,et al: No reduction of bone metastases with adjuvant clodronate in node positive breast cancer patients. ASCO Proc 1999, 489.

  3. Peters W,et al: A prospective randomised comparison of 2 doses of combination alkalating agents (AA) as consolidation after CAF in high risk primary breast cancer involving 10 or more axillary lymph nodes; Preliminary results of CALGB9082/SWOG 91104/NCICMA-13. ASCO Proc 1999, 2.

  4. Scandinavian Breast Cancer Study Group: Results from a randomised adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologus bone marrow stem cells versus dose escalating and tailored effect therapy. 9401 (J Bergh), Abstract 3.

  5. Bezwoda WR: Randomised controlled trial of high dose chemotherapy (HDCNVp) versus standard dose CAF chemotherapy for high risk surgically treated primary breast cancer. p2a, Abstract 4.

  6. Cameron D,et al: Mathematical model of response in primary chemotherapy for breast cancer.Br J Cancer 73:1409–1416, 1996.

    PubMed  CAS  Google Scholar 

  7. Norton L,et al: Overall survival (OS) advantage to simultaneous chemotherapy plus humanised anti HER2 monoclonal antibody Herceptin in HER2; Overexpressing metastatic breast cancer. ASCO Proc 1999, 483

  8. Early Breast Cancer Trialists Group: Tamoxifen for early breast cancer; An overview of randomised trials.Lancet 351:1451–1467, 1998.

    Article  Google Scholar 

  9. EBCTG: Polychemotherapy for early breast cancer; Overview of randomised trials.Lancet 352:930–942, 1998.

    Article  Google Scholar 

  10. Levine MM,et al: Randomised trial of intensive cyclophosphamide, epirubicin and 5 fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in pre menopausal woman with node positive breast cancer.J Clin Oncol 16:2651–2658, 1998.

    PubMed  CAS  Google Scholar 

  11. Coombes RC,et al: Adjuvant cyclophosphamide, methotrexate and 5 fluorouracil versus fluorouracil, epirubicin and cyclophosphamide chemotherapy in pre menopausal woman with axillary node positive operable breast cancer; Results of a randomised trial.J Clin Oncol 14:35–45, 1996.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Unit, Western General Hospital, Crewe Road South, EH4 2XU, Edinburgh, UK

    Robert C. F. Leonard

Authors
  1. Robert C. F. Leonard
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Leonard, R.C.F. Intensive adjuvant chemotherapy for breast cancer. Breast Cancer 6, 386–390 (1999). https://doi.org/10.1007/BF02966460

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02966460

Key words

Search

Navigation